Press releases

RaySearch Laboratories AB (publ) Interim report January 1 – September 30, 2007

• Net sales for the period amounted to SEK 50.2 M (47.8)
• Profit after tax was SEK 16.8 M (16.5)
• Earnings per share after tax amounted to SEK 1.47 (1.44)
• Operating profit amounted to SEK 22.1 M (22.5)
• Cash flow from operating activities amounted to SEK 25.7 M (16.9)
• New collaboration agreement with Varian Medical Systems was signed in May
• New collaboration agreement with TomoTherapy was signed in August
• Application to the FDA for 510(k) approval for sales of COMPASS product platform in the US was submitted in August.


“We are now working intensely on expanding our product portfolio and recently returned home from the major, annual ASTRO meeting at which we and three of our partners demonstrated new product concepts that will be launched in the coming years,” says Johan Löf, CEO of RaySearch.

“We are now entering a highly exciting period with many new product releases, but it is also pleasing that sales of our existing products continue the positive trend.”